Search | Clinical Trials Finder

Conditions: Pregnancy Related, Atopic Dermatitis
Interventions: Ruxolitinib Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 958 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Corticosteroid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 3 Months to 18 Months
Enrollment: 1,091 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 36
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more

Conditions: Vulvodynia, Vestibulodynia, Vulvar Diseases, Vulvar Vestibulitis, Vulvar Pain
Interventions: BioNourish, a component of the Flourish HEC kit, Control - no intervention; Device · Other
Lead sponsor: Vaginal Biome Science; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Virginia Beach, Virginia

Conditions: Molluscum Contagiosum
Interventions: 10% East Indian sandalwood oil cream, Placebo Cream; Drug
Lead sponsor: ViroXis Corporation; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type2 Diabetes, Cardiovascular Diseases
Interventions: Peanut, High carbohydrate snack; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Acne Vulgaris
Interventions: UHE-101 Cream, Vehicle Cream; Drug · Other
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hidradenitis Suppurativa
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 67
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 57 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Phototoxicity
Interventions: MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation, MC2-01 vehicle, no irradiation, Control, irradiation; Drug
Lead sponsor: MC2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
Interventions: topical ruxolitinib 1.5% cream, Topical vehicle/moisturizer cream; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Acneiform Rash, Papulopustular Eruption
Interventions: Triamcinolone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hyperpigmentation, Melasma, Dark Spots
Interventions: Facial Cleanser, Facial Moisturizer, Sunscreen SPF 55; Other
Lead sponsor: Revision Skincare; Industry
Eligibility: 20 Years to 60 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Irving, Texas

Conditions: Wound of Skin, Non-melanoma Skin Cancer, Skin Graft Complications, Wound of Lower Leg, Wound of Knee
Interventions: Nanofat-seeded biological scaffold on surgical defect; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: placebo, CT 327; Drug
Lead sponsor: Creabilis SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Charlotte, North Carolina • Wilmington, North Carolina • Winston-Salem, North Carolina + 2 more

Conditions: Atopic Dermatitis, Atopic Disorders, Eczema, Atopic Eczema
Interventions: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 1 Day to 63 Days
Enrollment: 1,260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Denver, Colorado • Durham, North Carolina • Portland, Oregon + 1 more

Conditions: Non-segmental Vitiligo
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 34
States / cities: Gilbert, Arizona • Fremont, California • Irvine, California + 24 more

Conditions: Acute Pain
Interventions: Arginine vasopressin, Saline, Observational learning, fMRI data aquisition; Drug · Other · Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: PF-06700841, Vehicle (Placebo); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 28 more

Conditions: Polycystic Ovary Syndrome
Interventions: Progesterone Vaginal Gel 8%, Letrozole Oral Tablet, pelvic ultrasound, Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe, Intrauterine insemination or timed intercourse; Drug · Diagnostic Test · Other
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Actinic Keratosis
Interventions: AM001 Cream, 7.5%, Vehicle Cream; Drug
Lead sponsor: AmDerma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions: Alprostadil, Placebo; Drug · Other
Lead sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.); Industry
Eligibility: 18 Years to 79 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more

Conditions: Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient
Interventions: Topical niacinamide 5% cream, Sunscreen; Drug
Lead sponsor: Marissa Lobl; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Plaque Psoriasis
Interventions: roflumilast cream 0.3%, Zoryve, Placebo; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Louisville, Kentucky

Search by objective public record fields.

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Effects of Flourish HEC on Localized Provoked Vulvodynia

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum

Peanuts and Glycemic Control

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

A 4-week Study Investigating Two Targeted Brightening Serum (A and B) Versus 4% Hydroquinone in Women With Mild to Severe Full-face Hyperpigmentation

Efficacy and Safety of a Nanofat-seeded Biological Scaffold in Healing Lower Limb Surgical Defects

CT 327 in the Treatment of Psoriasis Vulgaris

A Community-based Assessment of Skin Care, Allergies, and Eczema

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

Vasopressin and Pain Perception in the Brain

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis